Striking A Balance Between Speed And Quality To Deliver Next-Generation Therapeutics

By Dr. Fay Saunders, Director of Mammalian Cell Culture, Process Development

The therapeutic potential of bispecific antibodies (BsAbs) has become increasingly compelling for drug developers looking to generate molecules that unlock novel targets. Currently, there are over 200 different types of bispecific molecules with more than a hundred under clinical evaluation for cancer treatment; most remain in the early development stages while four have been approved by the FDA.

As more versions emerge, pharma companies and contract development and manufacturing organizations (CDMOs) must determine how to produce these molecules efficiently while maintaining control over quality attributes and safety profiles. Their unique structure, size, and complexity can lead to challenges with gene expression, analysis, purity, and stability. Download the full whitepaper to learn more about the importance of working with a CDMO that offers leading analytical and processing technologies to ease the path to commercialization.